Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

Launched by CENTRE HOSPITALIER RÉGIONAL D'ORLÉANS · Feb 18, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases," is looking at how compounds found in cannabis, called phytocannabinoids (like CBD and THC), might help reduce inflammation and improve immune responses in patients with various autoimmune diseases. These diseases, such as rheumatoid arthritis, psoriatic arthritis, and lupus, affect around 5 to 7% of people in Western countries and can impact different organs in the body. The researchers want to understand how different combinations of phytocannabinoids can affect inflammation in these conditions.

To be eligible for this study, participants need to be at least 18 years old and have a diagnosis of one of the specified inflammatory disorders confirmed by a doctor. They should also be receiving certain routine treatments for their conditions. If someone decides to participate, they will have a small amount of blood drawn during a regular check-up, which will be used to study how their immune cells respond to various cannabis extracts in the lab. The trial is not yet recruiting participants, so interested individuals should stay tuned for more information on when the study begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female ≥ 18 years old
• • 2. Diagnosis confirmed by a rheumatologist of RA or spondyloarthropathy (with or without IBD) or psoriatic arthritis (with or without active psoriasis) or systemic lupus erythematosus or Sjögren's disease
• • 3. Patient who has expressed consent to participate in the study
• • 4. Patients affiliated to social security
• • 5. Treatments authorized as part of routine care: non-steroidal anti-inflammatory drugs (NSAIDs), level 1 to 3 analgesics, local corticosteroids, oral corticosteroid therapy (daily dose ≤15 mg/d), 5-aminosalicylic acid, salazopyrine, methotrexate, leflunomide, hydroxychloroquine, biotherapies and targeted therapies.
• Exclusion Criteria:
• • 1. Patient who received intravenous corticosteroid therapy less than 4 weeks ago
• • 2. Patient receiving oral corticosteroid therapy with a daily dose \>15 mg/day
• • 3. Consumption of CBD and/or recreational cannabis and/or positive saliva test for cannabis consumption and/or CBD
• • 4. Pregnant and lactating women
• • 5. Persons under guardianship or curatorship